Chronic Myeloproliferative Disorders Completed Phase 1 / 2 Trials for Ravuconazole (DB06440)

IndicationStatusPhase
DBCOND0028462 (Chronic Myeloproliferative Disorders)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00064311Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell TransplantationSupportive Care